Gh Research Plc (GHRS) Stock Price, Quote & News

Company Profile

GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression. It also develops GH002, an intravenous mebufotenin product candi...

Industry: Biotechnology

Sector: Healthcare

Phone: 353 1 437 8334

Website: www.ghres.com

Address:

Joshua Dawson House, Dawson Street, Dublin, Ireland

Quantumup Jul. 13 at 8:19 PM

Jefferies: $CMPS $ATAI $GHRS $HELP $DFTX Jefferies: on September 14, the FDA will host a public hearing to discuss issues associated with psychedelic drugs in supervised and supportive settings. The finalized 2026 guidance focuses on generating interpretable efficacy data and suggests the agency remains receptive to helping sponsors, such as CMPS, DFTX, ATAI, HELP, and GHRS, succeed—a friendlier regulatory environment should make psychedelics a more investable space.

0 · Reply

firetypecracker Jul. 13 at 7:34 PM

$HELP NEWS TODAY: Jefferies says guidance suggests FDA receptive to helping psychedelic sponsors Jefferies notes that on September 14, the FDA will host a public hearing to discuss “issues” associated with psychedelic drugs in supervised and supportive settings. The finalized 2026 guidance focuses on generating interpretable efficacy data and suggests the agency remains receptive to helping sponsors, such as Compass Pathways ($CMPS), Definium Therapeutics ($DFTX), AtaiBeckley ($ATAI), Helus Pharma ($HELP), and GH Research ($GHRS), succeed, the analyst contends. A “friendlier regulatory environment should make psychedelics a more investable space,” the analyst added. https://www.tipranks.com/news/the-fly/jefferies-says-guidance-suggests-fda-receptive-to-helping-psychedelic-sponsors-thefly-news

0 · Reply

Fugazi_ Jul. 5 at 11:43 PM

$GHRS any clue about upcoming pipelines? Seems like someone bought 35C, 11 days expiry

0 · Reply

Solomonwisdom7 Jun. 27 at 8:56 PM

$CMPS $DFTX $GHRS $HELP What impact do you think the 10.3 million share shelf offering at an offering price of 4.85/share is going to have on the share price?

4 · Reply

topstockalerts Jun. 27 at 2:00 AM

$GHRS that was an unusually clean move.

0 · Reply

Buccabrian Jun. 26 at 9:03 PM

$HELP $DFTX $CMPS $GHRS

0 · Reply

MichaelNaussCMT Jun. 26 at 9:00 PM

$CMPS $DFTX $GHRS $HELP low market caps and under performance happens for a reason. The market is smart.

3 · Reply

Sowa5000 Jun. 26 at 7:37 PM

$HELP this is a winner 🏆 Breakthrough status, low market cap compared to competitors, peak market sales in $2-$5B..just need to get passed the finish line..like the space $DFTX $CMPS $GHRS

2 · Reply

cardinalrunner Jun. 26 at 7:18 PM

$GHRS why’d I only buy 1 share?- I was putting it on my watchlist and liked it enough to just purchase one outright. Should’ve added a few zeros to that…

0 · Reply

B8nm8nn8 Jun. 26 at 2:17 PM

$GHRS

0 · Reply

GH Research announces publication of Phase 2a results for mebufotenin

Jun 4, 2026, 7:00 AM EDT - 5 weeks ago

GH Research Announces Publication of Phase 2a Postpartum Depression Results

2026-05-19T10:07:01.000Z - 2 months ago

GH Research price target lowered to $65 from $70 at H.C. Wainwright

2026-05-15T13:46:38.000Z - 2 months ago

GH Research price target raised to $35 from $25 at Cantor Fitzgerald

2026-05-15T09:40:42.000Z - 2 months ago

GH Research price target lowered to $39 from $42 at Citizens

2026-05-14T18:50:44.000Z - 2 months ago

Psychedelic: Compass Pathways, AtaiBeckley, GH Research report earnings

ATAI CMND CMPS DFTX ENVB MIRA NRXP

May 14, 2026, 12:30 PM EDT - 2 months ago

GH Research Earnings release: Q1 2026

2026-05-14T13:56:44.000Z - 2 months ago

GH Research files $400M mixed securities shelf

2026-05-14T12:33:38.000Z - 2 months ago

GH Research reports Q1 EPS (31c), consensus (26c)

May 14, 2026, 8:00 AM EDT - 2 months ago

GH Research Registration statement: Registration filing

May 14, 2026, 7:00 AM EDT - 2 months ago

GH Research Reports First Quarter 2026 Financial Results and Provides Business Update

May 14, 2026, 7:00 AM EDT - 2 months ago

GH Research Slides: Corporate presentation

Apr 29, 2026, 8:00 AM EDT - 2 months ago

GH Research Announces Pricing of $117.5 Million Underwritten Offering

Apr 20, 2026, 2:05 PM EDT - 3 months ago

How Trump's psychedelics executive order could unlock stalled cannabis reform

ATAI CMPS DFTX HELP

Apr 20, 2026, 10:45 AM EDT - 3 months ago

Psychedelic Stocks Surge After Trump Signs Order Fast-Tracking Drug Research

ATAI CMPS DFTX

2026-04-20T14:00:40.000Z - 3 months ago

GH Research ‘welcomes’ Executive Order to accelerate mental illness treatments

Apr 20, 2026, 9:00 AM EDT - 3 months ago

GH Research Welcomes White House Executive Order to Accelerate Medical Treatments for Serious Mental Illness

Apr 20, 2026, 8:26 AM EDT - 3 months ago

Psychedelic stocks rally with Trump's support

ATAI CMPS DFTX

Apr 20, 2026, 8:18 AM EDT - 3 months ago

Trump Signs Order to Fast-Track Psychedelic Drugs. AtaiBeckley and These Other Stocks Are Soaring.

ATAI CMPS DFTX

Apr 20, 2026, 6:43 AM EDT - 3 months ago

Psychedelic drug makers rally as Trump orders FDA to expedite reviews

ATAI CMPS DFTX ENVB HELP

2026-03-25T15:15:16.000Z - 3 months ago

GH Research announces publication of Phase 2b results for mebufotenin

Mar 25, 2026, 11:10 AM EDT - 3 months ago

GH Research Announces Publication of Phase 2b Results for Mebufotenin (GH001) in JAMA Psychiatry and Reports New Finding of Severity-Independent Efficacy in TRD

2026-03-10T11:01:34.000Z - 4 months ago

GH Research price target raised to $34 from $29 at Guggenheim

2026-03-06T10:46:32.000Z - 4 months ago

GH Research price target raised to $42 from $39 at Citizens

Mar 5, 2026, 7:00 AM EST - 4 months ago

GH Research Reports Full Year 2025 Financial Results and Provides Business Update

Mar 5, 2026, 7:00 AM EST - 4 months ago

GH Research Earnings release: Q4 2025

Mar 5, 2026, 7:00 AM EST - 4 months ago

GH Research Annual report: Q4 2025

Mar 5, 2026, 7:00 AM EST - 4 months ago

GH Research Slides: Corporate presentation

Jan 5, 2026, 7:00 AM EST - 6 months ago

GH Research Announces FDA Lifts Clinical Hold on GH001, Clearing Path for Global Phase 3 Initiation in 2026

Jan 2, 2026, 4:01 PM EST - 6 months ago

GH Research to Announce IND Status for GH001

Nov 6, 2025, 7:00 AM EST - 8 months ago

GH Research Reports Third Quarter 2025 Financial Results and Provides Business Updates

Nov 5, 2025, 6:00 PM EST - 8 months ago

GH Research Earnings release: Q3 2025

Oct 9, 2025, 7:00 AM EDT - 9 months ago

GH Research Announces Novel Therapies Symposium Presentation and Posters at the 2025 ECNP Congress

Aug 7, 2025, 7:00 AM EDT - 1 year ago

GH Research Reports Second Quarter 2025 Financial Results and Provides Business Updates

Aug 6, 2025, 6:00 PM EDT - 1 year ago

GH Research Earnings release: Q2 2025

Jul 23, 2025, 8:00 AM EDT - 1 year ago

GH Research Announces Global Pivotal Program Plans and Further Development Updates

Jun 20, 2025, 1:00 PM EDT - 1 year ago

GH Research Submits Complete IND Hold Response to FDA Ahead of Schedule

May 15, 2025, 7:00 AM EDT - 1 year ago

GH Research Announces Acceptance of Pharmaceutical Pipeline Presentation and Late-Breaking Posters at the American Society of Clinical Psychopharmacology 2025 Annual Meeting

May 8, 2025, 7:00 AM EDT - 1 year ago

GH Research Reports First Quarter 2025 Financial Results and Provides Business Updates

May 7, 2025, 6:00 PM EDT - 1 year ago

GH Research Earnings release: Q1 2025

Feb 27, 2025, 9:30 AM EST - 1 year ago

GH Research Earnings release: Q4 2024

Feb 27, 2025, 9:30 AM EST - 1 year ago

GH Research Annual report: Q4 2024

Feb 27, 2025, 7:00 AM EST - 1 year ago

GH Research Reports Full Year 2024 Financial Results and Provides Business Updates

Feb 27, 2025, 7:00 AM EST - 1 year ago

GH Research Registration statement: Registration Filing

Feb 4, 2025, 8:52 PM EST - 1 year ago

GH Research Announces Pricing of $150 Million Public Offering

Feb 3, 2025, 4:03 PM EST - 1 year ago

GH Research Announces Proposed Public Offering

Feb 3, 2025, 8:00 AM EST - 1 year ago

GH Research Transcript: Status Update

Feb 3, 2025, 8:00 AM EST - 1 year ago

GH Research Press release: Status Update

Feb 3, 2025, 7:00 AM EST - 1 year ago

GH Research Announces Primary Endpoint Met in Phase 2b Trial with GH001 in TRD Demonstrating -15.5 Point Placebo-adjusted MADRS Reduction

Jan 31, 2025, 4:01 PM EST - 1 year ago

GH Research to Provide Update on Phase 2b Trial with GH001 in TRD

Jan 10, 2025, 7:00 AM EST - 1 year ago

GH Research Announces Primary Endpoint Met in Two Phase 2a POC Trials with GH001 and Completion of All FDA Requests to Address IND Hold with No Findings of Respiratory Toxicity in Non-Rodents

Nov 14, 2024, 7:00 AM EST - 1 year ago

GH Research Reports Third Quarter 2024 Financial Results and Provides Business Updates

Nov 13, 2024, 6:00 PM EST - 1 year ago

GH Research Earnings release: Q3 2024

Sep 3, 2024, 7:05 AM EDT - 2 years ago

GH Research Reports Second Quarter 2024 Financial Results and Provides Business Updates

Sep 3, 2024, 7:00 AM EDT - 2 years ago

GH Research Announces Appointment of Dr. Velichka “Villy” Valcheva to Chief Executive Officer

Sep 2, 2024, 6:00 PM EDT - 2 years ago

GH Research Earnings release: Q2 2024

May 3, 2024, 7:00 AM EDT - 2 years ago

GH Research Reports First Quarter 2024 Financial Results and Provides Business Updates

May 3, 2024, 7:00 AM EDT - 2 years ago

GH Research Earnings release: Q1 2024

Feb 29, 2024, 7:00 AM EST - 2 years ago

GH Research Reports Full Year 2023 Financial Results and Provides Business Updates

Feb 29, 2024, 7:00 AM EST - 2 years ago

GH Research Annual report: Q4 2023

Feb 29, 2024, 7:00 AM EST - 2 years ago

GH Research Earnings release: Q4 2023

Jan 18, 2024, 4:30 PM EST - 2 years ago

GH Research Announces Grant of European Patent Covering all Mebufotenin (5-MeO-DMT) and Mebufotenin Salt Products For Use in the Treatment of Major Depressive Disorder and Treatment-Resistant Depression

Nov 9, 2023, 4:45 PM EST - 2 years ago

GH Research Reports Third Quarter Financial Results and Provides Business Updates

Nov 9, 2023, 7:00 AM EST - 2 years ago

GH Research Earnings release: Q3 2023

Sep 29, 2023, 4:45 PM EDT - 3 years ago

GH Research Provides Updates and Guidance on its Clinical Development Program for GH001 in Treatment-Resistant Depression

Aug 23, 2023, 7:00 AM EDT - 3 years ago

GH Research Reports Second Quarter 2023 Financial Results and Provides Business Updates

Aug 23, 2023, 7:00 AM EDT - 3 years ago

GH Research Earnings release: Q2 2023

May 11, 2023, 7:30 AM EDT - 3 years ago

GH Research Reports First Quarter 2023 Financial Results and Provides Business Highlights

May 11, 2023, 7:00 AM EDT - 3 years ago

GH Research Earnings release: Q1 2023

Mar 9, 2023, 7:00 AM EST - 3 years ago

GH Research Registration statement: Registration Filing

Mar 2, 2023, 7:00 AM EST - 3 years ago

GH Research Reports Full Year 2022 Financial Results and Provides Business Updates

Mar 2, 2023, 7:00 AM EST - 3 years ago

GH Research Annual report: Q4 2022

Mar 2, 2023, 7:00 AM EST - 3 years ago

GH Research Earnings release: Q4 2022

Jan 9, 2023, 7:30 AM EST - 3 years ago

GH Research Provides Business Updates and Highlights Key Upcoming Milestones

Nov 10, 2022, 7:05 AM EST - 3 years ago

GH Research Reports Third Quarter 2022 Financial Results and Provides Business Updates

Nov 10, 2022, 7:00 AM EST - 3 years ago

GH Research Earnings release: Q3 2022

Aug 23, 2022, 7:00 AM EDT - 4 years ago

GH Research Reports Second Quarter 2022 Financial Results and Provides Business Updates

Aug 23, 2022, 7:00 AM EDT - 4 years ago

GH Research Earnings release: Q2 2022

May 18, 2022, 7:00 AM EDT - 4 years ago

GH Research Reports First Quarter 2022 Financial Results and Provides Business Updates

May 18, 2022, 7:00 AM EDT - 4 years ago

GH Research Earnings release: Q1 2022

Mar 28, 2022, 7:04 AM EDT - 4 years ago

GH Research Reports Full Year 2021 Financial Results and Provides Business Updates

Mar 28, 2022, 7:00 AM EDT - 4 years ago

GH Research Annual report: Q4 2021

Mar 28, 2022, 7:00 AM EDT - 4 years ago

GH Research Earnings release: Q4 2021

Dec 6, 2021, 7:10 AM EST - 5 years ago

GH Research Reports Third Quarter 2021 Financial Results and Provides Business Updates

Dec 6, 2021, 7:00 AM EST - 5 years ago

GH Research Earnings release: Q3 2021

Sep 23, 2021, 5:25 PM EDT - 5 years ago

GH Research PLC Provides Business Updates and Reports Second Quarter 2021 Financial Results

Jun 25, 2021, 1:23 PM EDT - 5 years ago

7 Companies Go Public Today. What Investors Need to Know.

ELEV MCW TKNO ACXP

Quantumup Jul. 13 at 8:19 PM

0 · Reply

firetypecracker Jul. 13 at 7:34 PM

0 · Reply

Fugazi_ Jul. 5 at 11:43 PM

$GHRS any clue about upcoming pipelines? Seems like someone bought 35C, 11 days expiry

0 · Reply

Solomonwisdom7 Jun. 27 at 8:56 PM

$CMPS $DFTX $GHRS $HELP What impact do you think the 10.3 million share shelf offering at an offering price of 4.85/share is going to have on the share price?

4 · Reply

topstockalerts Jun. 27 at 2:00 AM

$GHRS that was an unusually clean move.

0 · Reply

Buccabrian Jun. 26 at 9:03 PM

$HELP $DFTX $CMPS $GHRS

0 · Reply

MichaelNaussCMT Jun. 26 at 9:00 PM

$CMPS $DFTX $GHRS $HELP low market caps and under performance happens for a reason. The market is smart.

3 · Reply

Sowa5000 Jun. 26 at 7:37 PM

$HELP this is a winner 🏆 Breakthrough status, low market cap compared to competitors, peak market sales in $2-$5B..just need to get passed the finish line..like the space $DFTX $CMPS $GHRS

2 · Reply

cardinalrunner Jun. 26 at 7:18 PM

$GHRS why’d I only buy 1 share?- I was putting it on my watchlist and liked it enough to just purchase one outright. Should’ve added a few zeros to that…

0 · Reply

B8nm8nn8 Jun. 26 at 2:17 PM

$GHRS

0 · Reply

outlawinvestor1 Jun. 25 at 2:07 PM

$HELP $ATAI $DFTX $CMPS $GHRS helus still has quite a bit of room to catch-up with it's peers (atai, definium, compass).

1 · Reply

directorwalsh Jun. 25 at 2:02 AM

$DFTX or maybe people are starting to understand that the TAM for DT120 is more or less equivalent to the entire mental health crisis in the US Their pipeline (which will continue to expand) deserves a massive premium Pyschedelics will have a similar awakening as GLP1s. Stabbing yourself with a needle everyday was crazy until you lost 50lbs in a year $CMPS $ATAI $GHRS

1 · Reply

topstockalerts Jun. 23 at 7:18 PM

$GHRS this chart is slowly winning people over.

0 · Reply

stoxx0007 Jun. 23 at 7:04 PM

$GHRS whats going on over here?!!

0 · Reply

B8nm8nn8 Jun. 23 at 6:54 PM

$GHRS

0 · Reply

outlawinvestor1 Jun. 22 at 5:38 PM

$HELP $ATAI $DFTX $CMPS $GHRS upcoming hlp-003 mdd data up next. let's see if they can replicate or exceed their phase 2 data.

0 · Reply

machusa Jun. 5 at 8:02 PM

$GHRS $ATAI started small positions in these after the market beat down. Bought and holding $CMPS mid-May. These are small plays regarding the encouraged development of psilocybin therapy that may 10x in the future.

1 · Reply